SQZ Biotech
134 Coolidge Ave
Second Floor
Watertown
MA
02472
United States
Tel: (603) 490-9117
Website: http://sqzbiotech.com/
84 articles about SQZ Biotech
-
SQZ Biotechnologies Announces Generation of Dopaminergic Neurons from Human Pluripotent Stem Cells Through Single-Step Delivery of Six Cell-Fate Encoding RNAs
6/16/2022
SQZ Biotechnologies Company, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, presented preclinical regenerative medicine data showing that the company’s proprietary Cell Squeeze® technology can effectively generate dopaminergic neurons from human-induced pluripotent stem cells through the single-step delivery of six RNA that encode for specific fate-determining transcription factors.
-
SQZ Biotechnologies to Present at Jefferies Healthcare Conference - June 01, 2022
6/1/2022
SQZ Biotechnologies, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies, will present at the Jefferies Healthcare Conference on June 8, in New York, NY.
-
SQZ Biotechnologies Appoints Marshelle Smith Warren, M.D., as Chief Medical Officer
5/31/2022
SQZ Biotechnologies, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, announced that it has appointed Marshelle Smith Warren, M.D., as Chief Medical Officer.
-
SQZ Biotechnologies Announces Integrated Point-of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process
5/18/2022
SQZ Biotechnologies announced that the company’s first generation, integrated point-of-care cell therapy manufacturing system demonstrated superior process performance and comparable or improved product specifications relative to current clean room-based processes used in clinical development.
-
SQZ Biotechnologies Reports First Quarter 2022 Financial Results and Recent Portfolio Updates
5/10/2022
SQZ Biotechnologies Reports First Quarter 2022 Financial Results and Recent Portfolio Updates.
-
SQZ Biotechnologies to Host Live & Virtual R&D Investor Event on May 19, 2022
5/5/2022
SQZ Biotechnologies today announced that the company will host a live R&D investor event with optional virtual participation on Thursday, May 19, 2022, from 4:05 - 5:30 p.m. ET.
-
SQZ Biotechnologies Announces First Data Presentation on Non-Clinical Studies of Point-of-Care Manufacturing System and Collaboration with STEMCELL Technologies on Research-Use-Only System to Fuel Preclinical Research
5/5/2022
SQZ Biotechnologies announced that the company will present data from the first non-clinical studies of its point-of-care manufacturing system at the 2022 American Society for Gene and Cell Therapy Annual Meeting on May 18.
-
SQZ Biotechnologies to Present at Upcoming Investor Conferences in May 2022
5/3/2022
SQZ Biotechnologies announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies, will present at the Bank of America Securities 2022 Healthcare Conference on May 10, in Las Vegas, Nevada and at the H.C. Wainwright Global Investment Conference on May 25, in Miami, Florida.
-
SQZ Biotechnologies Receives FDA Fast Track Designation for its Lead Cell Therapy Candidate for the Treatment of HPV16+ Tumors
4/27/2022
SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the company’s lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors.
-
SQZ Biotechnologies Presents New eAPC Preclinical Data Demonstrating That Multiplexed mRNA Engineering of Immune Cells Increases Killer T Cell Activity In Vivo
4/11/2022
SQZ Biotechnologies, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, shared enhanced antigen presenting cell preclinical data demonstrating that delivery of multiple mRNAs encoding for disease-specific antigens together with immune stimulators had a synergistic effect that substantially increased killer T cells in humanized mouse models.
-
SQZ Biotechnologies to Present at Upcoming Investor Conferences - Apr 06, 2022
4/6/2022
SQZ Biotechnologies announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder of SQZ Biotechnologies, will present at the 21st Annual Needham Virtual Healthcare Conference on April 13, and Chardan’s 6th Annual Genetic Medicines & Cell Therapy Manufacturing Summit on April 26.
-
SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ® TAC Platform’s Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes
4/4/2022
SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ ® TAC Platform’s Ability to Induce Multiple Key Mechanisms of Antigen-Specific Tolerance and Protect Against Type 1 Diabetes.
-
Kenneth Frazier, executive chairman and former chief executive officer of Merck, joins former colleagues Roger Perlmutter and Roy Baynes at the well-financed company.
-
SQZ Biotechnologies Announces $2 Million Grant From the National Institutes of Health to Develop a Novel, Scalable Cell Replacement Therapy for Parkinson’s Disease
3/21/2022
SQZ Biotechnologies announced that it has been awarded a $2 million SBIR Phase II grant from the National Institute of General Medical Sciences, a division of the National Institutes of Health.
-
The 2022 International Conference on Alzheimer’s and Parkinson’s Disease ended last weekend, but it reported on numerous research studies and insights into the diseases.
-
SQZ Biotechnologies Reports Full Year 2021 Financial Results and Recent Portfolio Updates
3/16/2022
SQZ Biotechnologies, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, reported full year 2021 financial results and recent portfolio updates.
-
SQZ Biotechnologies to Present New Enhanced APC Platform Preclinical Findings and ENVOY-001 Phase 1/2 Clinical Trial in Progress Poster at the American Association for Cancer Research 2022 Annual Meeting
3/8/2022
SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it will present new preclinical findings on the company’s enhanced antigen presenting cell (eAPC) platform at the American Association for Cancer Research (AACR) Annual Meeting on April 8-13, 2022 in New Orleans, Louisiana.
-
SQZ Biotechnologies Announces Publication of Comprehensive Preclinical Research on SQZ® APC’s Ability to Overcome Fundamental Biological Barrier to Effective and Efficient Killer T Cell Activation
2/1/2022
SQZ Biotechnologies today announced the publication of comprehensive preclinical research on the company’s ability to engineer multiple immune cell types to drive MHC-I antigen presentation, a critical advance in the ability to drive a patient’s killer T cells to fight multiple diseases.
-
Clinical trial news definitely picked up this final week of January. Here’s a look.
-
SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors
1/24/2022
SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors.